ABM Respiratory Care has secured a $20 million growth capital commitment from Trinity Capital Inc, an international alternative asset manager, according to the company.
According to ABM, the financing will support its next phase of growth, with a focus on accelerating commercial expansion, strengthening its presence in existing and new markets, and advancing product innovation, clinical research, and connected respiratory care technologies.
“This financing represents an important milestone in ABM Respiratory Care’s continued growth,” said Greg Miller, Chief Executive Officer of ABM Respiratory Care. “Our partnership with Trinity Capital provides additional capital and flexibility to expand our commercial reach, build on the momentum of our BiWaze platform, and invest in technologies that support the evolving needs of patients and healthcare providers worldwide.”
ABMRC’s BiWaze platform includes two FDA-cleared respiratory therapy systems that address distinct airway clearance needs. BiWaze Clear delivers oscillating lung expansion therapy designed to mobilize secretions and support airway clearance in the lower airways, while BiWaze Cough provides mechanical insufflation-exsufflation therapy to assist patients with an ineffective cough in clearing secretions. Both technologies are designed for use across hospital and home care settings. The company continues to expand commercial access to these therapies while advancing clinical research and its Arc Connect digital health platform, designed to support patient engagement, therapy tracking, and greater visibility into respiratory therapy utilization for care teams.
“We are pleased to partner with ABM Respiratory Care as the company enters its next phase of growth,” said Rob Lake, Senior Managing Director, Healthcare & Life Sciences at Trinity Capital. “We believe in the company’s technology and its vision for expanding access to respiratory care solutions.”
Source: ABM Respiratory Care
